Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Ethnicity strongly linked to treatment resistance in schizophrenia

Patients with schizophrenia are at heightened risk for being resistant to treatment if they are White European, study findings reveal.

6 Feb 2013

Restricting gifts in medical school influences future prescribing behavior

US physicians who attended a medical school with a policy restricting acceptance of gifts from pharmaceutical companies are less likely to prescribe newly marketed drugs than physicians who were not exposed to such restrictions during training, according to research published in the BMJ.

5 Feb 2013

State roundup: Minn. officials want money for coverage expansion

Gov. Mark Dayton and his Human Services commissioner will travel to Washington, D.C., this week to lobby for federal money for MinnesotaCare. MinnesotaCare is a state-subsidized health plan that insures about 130,000 people under age 65. Dayton and Commissioner Lucinda Jesson are scheduled to meet Tuesday in Washington with Health and Human Services Secretary Kathleen Sebelius.

5 Feb 2013

Poor diet provides clue to metabolic abnormalities in schizophrenia

Patients with schizophrenia commonly have a poor diet, say UK researchers who believe this may partly account for the increased incidence of metabolic abnormalities in these patients.

4 Feb 2013

Mood disorder clinics improve bipolar disorder outcomes

Early treatment of patients with bipolar disorder in a specialized mood disorder clinic substantially reduces the risk for readmission to a psychiatric hospital, clinical trial findings show.

4 Feb 2013

Mood disorder clinics improve bipolar disorder outcomes

Early treatment of patients with bipolar disorder in a specialized mood disorder clinic substantially reduces the risk for readmission to a psychiatric hospital, clinical trial findings show.

31 Jan 2013

Undetected comorbidities linked to increased mortality in schizophrenia

Patients with schizophrenia have elevated mortality, the leading causes of which appear to be ischemic heart disease and cancer, a Swedish national cohort study shows.

25 Jan 2013

Pneumonia risk increased in schizophrenia

Patients with schizophrenia are at an increased risk for developing pneumonia, results from a large Taiwanese study show.

17 Jan 2013

Dopamine synthesis increased in patients at high risk for psychosis

UK study results show that patients at ultra-high risk for psychosis have elevated dopamine synthesis capacity in the dorsal striatum.

17 Jan 2013

Pneumonia risk increased in schizophrenia

Patients with schizophrenia are at an increased risk for developing pneumonia, results from a large Taiwanese study show.

16 Jan 2013

Vanderbilt University, AstraZeneca partner to identify candidate drugs for major brain diseases

Today, AstraZeneca and Vanderbilt University announced they have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer's disease and schizophrenia.

16 Jan 2013

White matter abnormalities may indicate genetic risk for bipolar disorder

White matter abnormalities in the right temporal lobe may be a marker of genetic risk for bipolar disorder, results from a US study suggest.

14 Jan 2013

Viewpoints: Rove says GOP unlikely to make much 'structural change' to entitlements; Roe anniversary and fading public understanding; Fast food workers' health insurance

As a matter of policy, rather than politics, it is no more sensible to draw the line at $620 billion in additional revenue over the next decade than to insist, as have some Democrats, that Medicare and Social Security remain untouched. The country's structural deficit poses too large a threat to future prosperity, and there is no politically or fiscally realistic scenario under which entitlement cuts alone can solve the problem.

11 Jan 2013

Cerebrospinal fluid IL-6 increased in schizophrenia

Cerebrospinal fluid levels of interleukin-6 are significantly increased in patients with schizophrenia and major depressive disorder, Japanese study results show.

9 Jan 2013

CRP40 may have pathogenic role in schizophrenia

Gene expression of catecholamine-regulated protein 40 is dysregulated in people with schizophrenia, study findings show.

7 Dec 2012

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications - schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs.

28 Nov 2012

Two-drug combo relieves agitation first time

The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.

8 Nov 2012

Antipsychotic drugs associated with increased mortality among people with schizophrenia

Results of a Johns Hopkins study suggest that individuals with schizophrenia are significantly more likely to live longer if they take their antipsychotic drugs on schedule, avoid extremely high doses and also regularly see a mental health professional.

2 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012